Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REGN 5713 5714 5715

Next Previous
X
Search
Drug Profile

REGN 5713 5714 5715

Alternative Names: Anti-Bet v 1 Monoclonal Antibodies; REGN 5713-5714-5715

Latest Information Update: 28 Aug 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antiallergics; Monoclonal antibodies; Tree pollen allergy immunotherapies
  • Mechanism of Action IgE receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Conjunctivitis; Seasonal allergic rhinitis

Most Recent Events

  • 31 Jul 2023 Regeneron Pharmaceuticals completes a phase-II trial for Conjunctivitis (In Volunteers) in Canada (SC) (NCT05430919)
  • 31 Jul 2023 Regeneron Pharmaceuticals completes a phase-II trial for Seasonal allergic rhinitis (In Volunteers) in Canada (SC)(NCT05430919)
  • 15 Aug 2022 Regeneron Pharmaceuticals initiates enrolment in a phase-II trial for Allergic Rhinitis (In Volunteers) in Canada (SC)(NCT05430919)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top